Frost.com - Healthcare Research http://www.frost.com/c/10024/home.do - Healthcare Research Mon, 1 May 2017 7:15:16 Top Technologies in Medical Devices & Imaging, 2017 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7C8-01-00-00-00 TechVision's Medical Devices and Imaging technology cluster's flagship research service profiles ten cutting-edge medical technologies that are expected to have a huge impact on the healthcare industry in the next two years. Each of technologies that have been profiled here represent billions of dollars in market potential, and have a rich track record of R&D funding, intellectual property (IP) activity and a vibrant innovation ecosystem. Each of the technology profiles covers the following: Brief technology snapshot, breadth of applications, key innovations and innovators, five-year market potential, recent funding and business deals, important market factors aiding and hindering growth. This research service aims to act as a guide for innovation-focused organizations who seek to learn about the medical technologies that will fuel growth in the next few years. This list includes technologies that are just seeing the light of commercialization, as well as those technologies that are already in the market, but are expected to make an impact through wide-spread adoption. This research service is a product of a year-long scout of the MedTech industry and other adjacent innovation clusters. This report aims to provide a snapshot of the ten technologies, service as a strategic guide to innovators and senior management, helping companies in innovation planning and decision-making. Fri, 28 Apr 2017 00:00:00 +0100 End-user and Decision-maker Survey of Southeast Asian PACS Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P96D-01-00-00-00 The research service provides an in-depth analysis of the Picture Archiving and Communication System (PACS) market across six Southeast Asian countries with a focus on end-user and radiology decision-maker needs, challenges, and vendor preferences. The study provides opportunity analysis, vendor landscape, and evolving technology and business model trends between 2016 and 2021. Key Target Audience: The study is an excellent starting point for both multinational imaging informatics leaders as well as local vendors aiming to enter and expand penetration in Southeast Asia. The research service is also relevant for healthcare providers, as it highlights the key challenges faced by radiologists and emerging technologies that can help improve the efficiency and service quality of the radiology department. Research Scope: At a compound annual growth rate (CAGR) of 6.8% between 2016 and 2021, the Southeast Asian PACS market represents a rapidly maturing sector with revenue opportunities for both new and renewal solutions. The market stands divided between two distinct types of consumers: the experienced PACS decision makers and the novices. Organizations that are currently investing in their second or third generation of PACS are well aware of the workflow issues that may arise due to an under-planned implementation. These experienced PACS decision makers are turning toward vendor-neutral solutions and heavily emphasize the need for better interoperability in the radiology department. Furthermore, several hospitals, especially in the Philippines and Vietnam, will be investing in their first PACS solution and are thus, more budget conscious and also want to take baby steps toward digitalization. Indonesia and Malaysia are the fastest growing countries in the region, followed closely by Thailand. Singapore represents a progressive market that is ready for sophisticated solutions including advanced viewers, imaging analytics, and decision support tools. The study provides further insights into target hospital segments and ideal channels for market penetration across each of these countries. A key finding of the study is that many PACS end users and decision makers feel that vendors do not collaborate enough with hospitals while building the solution. Healthcare providers would like to work with vendors who truly understand individual hospital workflows and then design solutions. While not so much interested in modularity, providers would certainly want their imaging IT solutions to be scalable, keeping in mind the fast pace of hospital infrastructure and services expansion in the region. Southeast Asian countries covered in this study: Indonesia Malaysia The Philippines Singapore Thailand Vietnam Key Questions This Study Will Answer: What is the market opportunity for PACS in Southeast Asia? Which countries and hospital segments represent opportunity hotspots for PACS? What are the unmet needs of target hospital segments and what are some vendor strategies for addressing these needs? How are vendors driving market entry and penetration? How will technological advancement fuel market growth, especially business model innovation? How will the competitive landscape evolve over the next five years? Fri, 28 Apr 2017 00:00:00 +0100 Top Technologies in Sensors and Instrumentation, 2017 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7C2-01-00-00-00 The technology and innovation research service covers the top 10 sensor and instrumentation technologies that will have highest impact in the near- to medium-term Key technologies in the sensor and instrumentation cluster were evaluated to arrive at the top 10 technologies for 2017. The technologies were selected after critical evaluation of an exhaustive list of technologies using TechVision's proprietary selection methodology. The research service assesses technologies from various aspects such as nature of disruption, key technology drivers, market potential, patents, funding, applications and megatrends impacted. The top 10 technologies covered in this research service are Biosensors, Touchless Sensing, Smart Haptics, ADAS, Electronic Skin/e-skin, Energy Harvesting, Drones, Robotics Sensors, Electronic Nose and Nanosensors. Fri, 28 Apr 2017 00:00:00 +0100 Innovations in Biomedical Imaging http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-13-00-00 The latest issue of Medical and Diagnostic Imaging TOE profiles innovations in biomedical imaging. Some of the profiles covered include magnetic resonance imaging (MRI) for targeted drug delivery, computerized blood flow simulation with MRI scans, next-generation contrast agents, upper extremity MRI modality, tablet-controlled computed tomography scanners, transoral robot-assisted high-resolution microendoscopic imaging, and newer applications of Raman spectroscopy. Medical and Diagnostic Imaging TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Targeted drug delivery, computerized blood flow simulation, upper extremity imaging, tablet-controlled computer tomography, robotic microendoscopic imaging, Raman spectroscopy Fri, 28 Apr 2017 00:00:00 +0100 Advancements across Skin Testing Sector http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-44-00-00 This Genetic Technology TOE depicts trends across the skin testing sector. Technology profiles for skin mimicking, tissue models, in vitro testing and tissue engineering approaches are presented. Clinical trials scenario for skin irritation testing is depicted along with the industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Cosmetic testing, skin patch test, skin sensitization, skin products, tissue engineering, epidermal models, skin irritation testing Fri, 28 Apr 2017 00:00:00 +0100 Emerging Woundcare Technologies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7AF-01-00-00-00 Wounds are known to have major impact on patient function and quality of life and may be even life-threatening. To address the range of complex wound care industry challenges, there is an influx of technologies such as sensor technology, information and communication technology, 3D printing technology or the advanced stem cells technology. Integration of these technologies into the wound care product can help improve care and patient outcomes, and give it a competitive advantage over the traditional wound care products. Thu, 27 Apr 2017 00:00:00 +0100 Future of Bionics http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7B1-01-00-00-00 This Research Service (RS) offers a strategic perspective on the global emerging industry of bionics technologies. This research service is segmented into three chapters, with the first two focusing on analysis of the top trends from both technology and end-user perspectives. The third chapter brings out the competitive landscape, focusing on strategic scenarios within the industry, reviewing the roles and strategies of both existing and emerging participants in the global market. Key questions answered in this research service: 1. What is the role played by NPD (new product development) and research initiatives in improving the overall adoption of bionic technologies? 2. What are the ongoing shifts in the healthcare needs which are largely driving research and development of bionic prosthetics? 3. What are the potential technology-enabled business models that could be explored by existing competitors, and new players entering into the global industry for the bionic prosthetics? 4. Investments in bionic technologies are expected to increase. What are the strategic priorities of existing and new participants in developing the global market? Wed, 26 Apr 2017 00:00:00 +0100 Internet of Medical Things (IoMT) Revolutionizing Healthcare http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7B0-01-00-00-00 As consumers take more responsibility of their own health and demand better access to their medical data, the process of extracting this data to provide meaningful insights needs an incremental change. In the next few years, advanced, connected and smarter patient monitoring devices will be available to consumers that will be able to gather real-time data including genetics and lifestyle behavior. This will help the IoMT market grow at a significant rate. Internet of Medical Things (IoMT) is an amalgamation of medical devices and applications that can connect to healthcare information technology (IT) systems using networking technologies. It connects patients to their physicians and allows transfer of medical data over a secure network, which in turn reduces unnecessary hospital visits and reduces the burden on healthcare systems largely. This research service evaluates the role played by networked devices and analytics in enabling digital healthcare transformation. Key questions answered in this study: 1. How internet of medical things (IoMT) differ from mobile healthcare technologies in improving the quality and reliability of healthcare infrastructure? 2. What is the role played by advanced computing techniques and analytics in secure storage, transmission and decoding of voluminous data over long distances by the use of IoMT? 3. How can IoMT enable clinicians to reliably use medical data in the process of making decisions for improving treatment for a variety disorders? 4. What is the role played by IoMT in securing critical clinical data from cyber and phishing attacks, preventing loss of medical data or leak of patient's medical history? Wed, 26 Apr 2017 00:00:00 +0100 Global Medical Device Industry Snapshot, 2017 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MC3C-01-00-00-00 Delivering value in the current dynamic healthcare environment will require a broad set of partnerships, relationships, and joint ventured initiatives. The breadth and scope of healthcare changes and range of different regional delivery systems all indicate that partnering models will be quite diverse. Realizing new insights, new approaches, and new sources of value within a meaningful time frame will require collaboration. The medical devices industry is experiencing an evolving reasoning for moving away from an input-based approach, that is, inputs from patients and physicians, to a value-and outcome-based approach, that is, improving the patient health outcomes. The main aim of this transformational shift is to provide the utmost benefit to a large population alongside a set of controlled resources. Despite global political uncertainties and a sluggish economic outlook, 2017 will be a significant year for the global medical devices industry that promises the partial realization of major health policies and initiatives. Future medical devices will be more targeted to meet the unique needs of emerging markets (such as China, India, and Brazil), which demonstrate high growth opportunities compared with saturated developed markets in the Western hemisphere. The pressure to reduce healthcare expenditure, intensifying competition, and consolidation of hospitals and health systems has resulted in unprecedented changes in the way medical device companies do business. The dynamic marketplace is transforming the traditional way of doing business and requires the medical device manufacturers to rethink their existing business models and create value proposition for customers through innovative products and solutions. This transformation of the medical device industry is fueled by ageing population, proliferation of chronic diseases, increasing emphasis on quality of care and treatment, stringent regulatory landscape focusing on patient safety and cost-containment, empowered and informed customers, and emerging technologies. Research Scope: The medical device industry has been analyzed for the 2016-2017 period. The global medical device market segment includes medical devices in cardiovascular, orthopedics, wound care, minimally invasive, neurology, endoscopy, anesthesia and respiratory, audiology, ophthalmology, urology & gynecology, aesthetics, and others such as durable medical equipment, hospital supplies, and so on. Geographic Region: Global Key questions this study will answer: What are the top trends that will drive the medical devices industry in 2017? What impact will these trends have on the market? What are the new business models, developments, and companies to watch out for in the medical devices industry in 2017? What was the size of the total medical device industry in 2016, and how is it expected to grow in 2017? What are the opportunities available for medical device manufacturers in key sectors in 2017? What are the key takeaways from Frost & Sullivan s CEO Survey? Mon, 24 Apr 2017 00:00:00 +0100 Innovations in Surgical Devices, Wound Management, Lab-on-chip Devices, and Cancer Biomarkers http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-10-00-00 The latest issue of the Medical Devices TOE profiles eight innovations spanning the breadth of the MedTech space. These include synthetic surgical adhesives and sealants, non-invasive biomarker analysis for early cancer detection, borate-based bioactive wound dressing, a nanoscale glass for lab-on-a-chip devices, and a wrist worn wearable and healthcare app for asthma management. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Synthetic surgical adhesives, sealants, biomarker analysis, bioactive wound dressing, flexible nanoscale, wrist worn wearable, asthma app Fri, 21 Apr 2017 00:00:00 +0100 Advances in Liquid Biopsy Platforms http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-43-00-00 This Genetic Technology TOE depicts trends across liquid biopsy platforms. The advent of novel antibody-based and targeted small molecule therapies have greatly improved the management of cancer disease. However, there is a growing need for robust monitoring platforms for enhanced assessment of diseases progression and treatment monitoring in cancer patients. Lung cancer clinical trials using liquid biopsy platforms are depicted along with industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Liquid biopsy platforms, cancer monitoring, free-floating genome, early cancer detection, circulating tumor DNA, chronic lymphocytic leukemia, extracellular vesicles Fri, 21 Apr 2017 00:00:00 +0100 Global CRO Market, 2016 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P94F-01-00-00-00 The Global CRO Market, Forecast to 2021, presents an overview and analysis of the global clinical trials and research outsourcing (CRO) market. It provides revenue forecasts for CROs globally by phase, therapeutic type and region. With the consolidation of the market as well as a higher cost and risk involved, the big companies are slowly shifting their business models towards a more collaborative business model and have started to look out for partners, giving rise to Bio analytics focused CROs. The research study also addresses some of the major issues and challenges alongside providing information on the key unmet needs and emerging trends in the market. The report also outlines market drivers and restraints, market engineering measurements as well as R&D trends. Alongside the challenges and opportunities, a special focus is given on the emerging trends and their importance across the current and future market scenario. The report also highlights some of the major shifts occurring in the CRO and Pharma ecosystem with the emergence of several new and innovative CRO players in the market with a specific focus on niche segments, such as bioanalytics and HEOR amongst others. Further to this, a detailed information will be provided on support services such as Central laboratory services, Bio analytics and Data management. The report covers the complete life cycle of CRO industry, starting from preclinical trials to post-marketing surveillance. One of the focus areas of this study would be bio analytics services, which is making a big impact in CRO industry. There is a major shift observed across the CRO landscape with several key pharma players now outsourcing their early drug development activities (pre-clinical and early phase research) to some of the leading CRO players in the market which was earlier handled by pharma companies themselves. Some of the key questions being answered by this report include: How will the contract research outsourcing help in drug development by saving time and cost for manufacturers? What is the impact of the market growth in different regions? Who are the dominant market participants in the CRO market and their market share contribution? What are the key market trends observed toward expansion of contract research organizations in drug development across key therapeutic areas? Do the products/services offered today meet customer needs or is additional development needed? What are the key segments to look out for and what are the key trends in the market? Wed, 19 Apr 2017 00:00:00 +0100 US Healthcare Data Analytics Market, Forecast to 2020 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K108-01-00-00-00 Introduction: A healthcare data analytics platform can be defined as a single, interoperable system that uses retrospective data to produce business intelligence reports that quantify enterprise-level financial and operational performance, as well as, disparate clinical data to enable predictive, real-time reporting of patient outcomes against every episode of care delivered. Research Overview: This study defines and describes the US healthcare data analytics market. It covers factors driving the need to adopt healthcare data analytics technologies that identify care leakages, automate patient-risk assessment, facilitate targeted intervention, support proactive member outreach, and benchmark enterprise-level clinical, financial, and operational utilizations. Additionally, the report will: Analyze key market drivers and restraints impacting end-user adoption Evaluate existing and emerging healthcare business models centered around data analytics Highlight best-practices in the areas of analytics budgeting, deployment, and governance Shortlist vendors that can provide best-in class solutions Forecast the gross revenue potential of the US healthcare analytics market over the next 5 years This study is segmented into three major analytics service segments as follows: Clinical Analytics Financial Analytics Operational Analytics In terms of end-user adoption, this study classifies the buyer market in two broad categories: Provider Organizations o Hospitals o Physician Practices Payer Organizations o Commercial and public payers including payer-viders Finally, the vendor market is stratified based on two key parameters: Product Relevance o Enterprise Platform o EMR Integrated Platform o Modular Suite of Solutions o Web-based Solutions Business Application Relevance o Clinical Solutions o Financial Solutions o Operational Solutions Healthcare analytics is widely regarded as a key enabler of value-based care. Robust usage of this technology allows health systems to practice data-driven decision making, which improves operational efficiencies, eliminates preventable costs, and streamlines clinical effectiveness. However, analytics adoption among US healthcare payers and providers is not consistent; healthcare organizations embrace a diverse array of deployment strategies that demonstrate different implementation maturity levels. For example, some health systems might utilize advanced enterprise data processing architecture to derive patient-specific insights for every episode of care, whereas others still rely on basic reporting capabilities of legacy Business Intelligence (BI) tools. This year, the cumulative maturity of the US analytics market is likely to be streamlined, mainly due to timely intervention from CMS. In late 2016, CMS launched the final rules for bundled payment programs, bringing great joy to analytics vendors that now anticipate higher traction from payers and providers. On the contrary, the end-user segment is still apprehensive about the feasibility of this new rule, which mandates that US providers in some regions accept financial accountability for the quality and cost of every episode of cardiac and orthopedic care. The scope of the new rule combines all patients being treated and all patients during the 90-day post-discharge phase; thus, encouraging effective care coordination between acute care hospitals, physician practices, and post acute-care providers. Providers managing to demonstrate episodic cost utilization below the CMS benchmark are likely to be incentivized and others are likely to be penalized. Regardless of this initiative s longevity amid political intervention and provider outburst, in 2017, healthcare organizations are likely to accelerate adoption of best-in-class analytics solutions, mainly for quality reporting, which is an integral component of value-based care and population health management. Providers are most receptive to using analytics solutions to identify, assess, and benchmark cost trends by payer, patient, and physician mix, whereas payers are likely to opt for these solutions to identify quality-adjusted target prices for every episode of care. Mon, 17 Apr 2017 00:00:00 +0100 Robotics in Drug Discovery http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-10-00-00 The introduction of automation and robotics into the drug discovery process has greatly enhanced the ability to explore and identify new drug candidates. Numerous chemical compounds can be manufactured and analyzed in a matter of a couple of weeks. Robotics can run tests on thousands of these compounds on biological samples for potential therapeutic activity. Artificial intelligence could redefine the manner in which drugs are discovered, leading to a whole new era of fast to market drugs. This would make the standard 15 year drug development value chain to become less than 5 years if the automation strategies and the robotics compliances are running in optimal and safe standards. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Robotics in drug discovery, robotic scientist, automation, drug discovery and development, reaction and processing using robots Fri, 14 Apr 2017 00:00:00 +0100 Advancements across Life Science Sector http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-42-00-00 This Genetic Technology TOE depicts the current landscape across life sciences sector. 3D tissue microenvironment tests, protein-based drugs manufacturing, skin testing, cosmetics developments, and crowdsourcing for clinical trials are profiled. The corresponding industry interactions are also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Cosmetic product development, 3D tissue microenvironments, drug testing, streamlining manufacturing, protein-based drugs, digitization, clinical trial, crowdsourcing, skin testing Fri, 14 Apr 2017 00:00:00 +0100 Developments in Screenless Displays http://www.frost.com/prod/servlet/sublib/display-report.do?id=D79C-01-00-00-00 Advancements in screenless displays have created opportunities for display manufactures to discover a wide range of solutions for multiple applications. Miniaturization of electronic components, advancements in wireless communications and navigation, and adoption of smart devices across various industries is expected to fuel advancements in the screenless display industry. Advancements in screenless displays can have a high impact across various applications. Though construction of 3D images, evolving form factors, and high data privacy features may drive opportunities, high initial investment and lack of consumer awareness are some of the key factors that hinder widespread adoption. This technology and innovation report focuses on capturing developments in visual image, virtual retinal, and synaptic interface screenless display forms. The report also includes other screenless display forms- holographic displays, heads-up displays, smart eye wear, and brain-computer interface. Key questions addressed in the technology report: What are the various categories of screenless displays? What are the different types of screenless display solutions that can be adopted in various applications? What are the factors influencing adoption of screenless display? What are the key patent and funding trends? What are the key innovations propelling R&D in screenless displays? What is the R&D pipeline for screenless displays? Thu, 13 Apr 2017 00:00:00 +0100 Therapeutic Breakthroughs in Alzheimer s and Parkinson s Diseases http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7B4-01-00-00-00 The research service primarily encompasses comprehensive analyses of key emerging therapies across AD and PD.The service includes treatment overviews, emerging therapeutic platforms, IP and funding analysis, and emerging innovation profiles across Alzheimer's and Parkinson's diseases. Furthermore, the research service features the impact of key technology drivers and restraints for the global AD and PD therapeutic industry. The research services also provides an summary of collaborative trends, regional adoption potential, emerging therapeutic platforms and novel growth opportunities across AD and PD. Wed, 12 Apr 2017 00:00:00 +0100 Emerging Robotic Exoskeleton Technologies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7A2-01-00-00-00 Robotic Exoskeleton has been experiencing significant technology enhancements in the recent years. This advanced technology is destined to play a critical role in transforming the everyday lives of people, especially patients with disabilities. It has opportunities in manufacturing, for instance in warehouse applications. Robotic exoskeletons can be classified into six main categories: Full body powered suits Limb assistance suits Back support suits Powered gloves Supernumerary robotic arms Tool holding exoskeletons Robotic exoskeletons are anticipated to impact the healthcare, military, and manufacturing industries significantly. The technology literally improves the physical strength, functionality, and performance of the user. The Emerging Robotic Exoskeleton Technologies technology and innovation report reviews the recent technology advancements and innovations impacting various industries. Key questions covered in this research service: What is the significance and impact of robotic exoskeleton technology across industries? What is the key industry trends propelling adoption? What are the major drivers and challenges? What are the key innovations? What is the patent and funding trend? Who are the key stakeholders? What is the technology roadmap for the next five years (2017-2022)? What are key growth opportunity areas? Fri, 7 Apr 2017 00:00:00 +0100 Recent Advances in Biopharmaceutical Technologies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-41-00-00 This Genetic Technology TOE profiles recent trends across biopharmaceutical technologies. The corresponding clinical trials are also depicted along with industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Immuno-oncology, bispecific antibody, nanobody platform, psoriasis management, predictive biomarkers, cancer immunotherapy, cancer therapy, CRISPR technology, drug target discovery Fri, 7 Apr 2017 00:00:00 +0100 Growth Opportunities in the US Telehealth Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K122-01-00-00-00 Telehealth services and systems have made the most progress in remote management of post-acute care patients or among patients with chronic conditions, many of whom have one or more co-morbidity. This progress is visible across 4 major segments: remote patient monitoring (RPM), virtual telehealth visits, mobile health (mHealth), and personal emergency response systems (PERS). This study finds the overall US telehealth market will grow by a compound annual growth rate (CAGR) of 29.3% from 2016 to 2021. One unique aspect of this research is the view that the larger segments of the telehealth market will stimulate some break-out growth in 14 sub-segment markets including: activity tracking, telebehavioral health, teledermatology, telediabetes management, telemedicine platforms, telepediatrics, tele-ICU, telecardiology, telestroke management, teleradiology/tele-Imaging, telehealth kiosks, telemedication management, telepharmacy, and other specialty areas. The study ranks the segments and sub-segments based on a variety of criteria ranging from short-term revenue opportunities to the transformative potential of each segment covered. The research finds the greatest opportunity will be associated with the mHealth segment because in addition to stimulating service via a large array of devices, and thousands of health-related apps, mHealth offers many enabling capabilities across all segments and sub-segments including connectivity and secure data transport. This study also covers a mix of large and smaller industry participants offering services including Medtronic Care Management Services, Philips Telehealth, American Well, Teladoc, Qualcomm Life, Vidyo, Zipnosis, Dexcom, Tactio, and many others. Key questions this research will answer address: What are telehealth services and how are these solutions being deployed by 4 key market segments healthcare payers, employer plans, hospitals, and physicians? What are the market-shifting macro trends impacting the need to deploy new or improved solutions to enable patients to achieve quality care using telehealth in a variety of settings? What are the specific drivers and restraints impacting the telehealth virtual visits market in the United States over the next 5 years? What are the sub-segments of the telehealth market and which ones offer the best opportunities for growth? What is the 6-year revenue outlook for the telehealth market and the major segments? Frost & Sullivan predicts that within 5 to 7 years telehealth will become a mainstream health option. The consumer or patient will be able to maintain an ongoing relationship with his/her physicians while enjoying greater ease of access. Meanwhile, the global proliferation of the Internet of Medical Things (IoMT) will reduce the number of new chronic condition patients. Thu, 6 Apr 2017 00:00:00 +0100 Analysis of Endoscopy Devices Repair Solutions in Europe http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD03-01-00-00-00 This research service covers both current and future market trends, drivers, and challenges in the European endoscope repair and maintenance industry. It analyses the endoscopy solutions repair market by applications such as arthroscopy, ENT, Gastrointestinal (GI), Gynecology, Laparoscopy, Neurology, Pulmonary, and Urology sectors. The analysis covers both rigid and flexible endoscopes and provides key market opportunities by different end-user categories such as hospitals, day care centres, and specialised clinics. The market opportunities are analyzed for two sets of endoscope repair market participants Original Equipment Manufacturers (OEMs) and Independent Service Organizations (ISOs). This research service also provides strategic insights on targeted growth opportunities for each set of participants. Tue, 4 Apr 2017 00:00:00 +0100 Global Digital Tools in Wound Assessment and Management, 2016 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K0F7-01-00-00-00 Wound assessment and monitoring systems are devices or digital aids that enable the measurement, imaging, and documentation of wounds by providing 3D assessment of a wound with EMR software integration. With inadequate wound care resulting in various debilitating healthcare-associated infections and adding to the cost burden of patients, modern digital tools are taking the guesswork out of wound care. Technologies like telehealth, smartphones, and now digital tools and aids for wound care and management are changing how hospitals carry out their daily workflows or how patients are being treated or receive care, with the ultimate goal of reducing hospital re-admissions and positive clinical outcomes. The inconsistent wound care outcomes have compelled the industry to deliver clinical and economic evidence, and improved care coordination through digital tools / guidelines for effective decision-making, acting as major growth opportunities that will boost the wound assessment and monitoring market growth. The digital age is fast becoming the go-to strategy for wound assessment and management, where doctors are able to let go of the tedious task of switching up treatments (sometimes, for years) for wounds with no improvements. Excellent efforts are underway to advance wound care by replacing rulers and swabs with smartphones and iPads. Innovation opportunities are present across the entire wound care and management continuum, right from prevention and diagnosis / detection solutions, to treatment and data-driven care co-ordination tools. Research Scope: This study includes a detailed description of modern digital tools and devices used for wound assessment and monitoring. The study also consists of detailed analysis of the current challenges and unmet needs in wound management, advances in wound management, in-depth description of the various innovative companies in the wound care data / heath information and early detection space as well as companies in the wound care planning, monitoring, and management space, and analysis of the key product features of each of these companies. The study concludes with key conclusions in this growing market. Key Questions This Study will Answer: 1. What are the challenges and unmet needs in the wound care industry? 2. How are the digital technologies assisting clinicians and hospitals in proper wound care and management? 3. Where are the innovation opportunities and advances in wound management? 4. Which are the current companies in the wound assessment and management space and what are their solutions? 5. What key product features should be present in a digital wound assessment tool or solution for efficient functioning and outcomes? Fri, 31 Mar 2017 00:00:00 +0100 Future of Diabetes Care Paradigms, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K180-01-00-00-00 Diabetes management is on the verge of being disrupted by innovative technologies such as artificial pancreas, non-invasive glucose monitoring sensors, wearables, apps, and inhalable insulin. This research study captures all the innovative developments across the segments of wellness, diagnosis, monitoring, and therapy of the diabetes care continuum, covering the global market. Diabetes remains one of the top causes of mortality, and health expenditure on the disorder and its complications is set to rise 19% annually until 2040, to reach $802 billion. Beyond the traditional focus and high-interest areas of monitoring and therapy, rising diabetes prevalence and costs are resulting in the focus gradually shifting to preventing diabetes, and on the overall wellbeing of diabetics and pre-diabetics, resulting in the highest double-digit growth of the wellness segment. Diagnosis, however, remains a neglected aspect of diabetes and novel approaches may be necessary to improve screening and diagnosing patients earlier to save on long-term costs. Monitoring developments that help improve the quality of life of diabetics include blood glucose monitoring tech advances (traditional glucometers and also semi-invasive, implants, and non-invasive continuous glucose monitoring systems), data analytics support, care delivery support, and overall diabetes management support in the form of apps, telehealth, and insulin dosing calculation support. Therapy, the largest segment, is also seeing several improvements in terms of better drugs, combination drugs, better insulin forms, and better delivery mechanisms. Of course, the main development in this segment is that of artificial pancreas there is one commercially available system and several being developed with varying approaches and features. The other notable permanent cure approach is cell therapy involving regenerative medicine techniques with variations in the approaches for transplantation. The study provides an exhaustive coverage of the overall diabetes ecosystem, with strong focus on startups, apart from the existing stakeholders. It also analyzes the role that technology giants such as Alphabet (n e Google) and IBM are playing in the diabetes space. An overview of several innovative diabetes care delivery models from across the world is also included. The study would be valuable for diabetes stakeholders to chart out their strategies for future collaborations and partnerships, while keeping a watchful eye on the competition. Key questions this study will answer: How is the diabetes burden evolving across the globe? How are market forces and trends shaping the diabetes market and the segments of wellness, diagnosis, monitoring, and therapy? What gaps in diabetic care need to be filled to address the unmet needs of diabetics? What are the technological developments in the industry that attempt to address such unmet needs? How have some care models perfected diabetes management, catering to local needs? What are some future perspectives for the industry? Fri, 31 Mar 2017 00:00:00 +0100 Recent FDA-approved Therapeutics http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-40-00-00 This Genetic Technology TOE profiles therapeutics that have been recently approved by FDA. The corresponding clinical trials scenario is also depicted along with industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Metastatic merkel cell carcinoma, FDA approval, immunotherapy, relapsing multiple sclerosis, atopic dermatitis, recurrent epithelial ovarian cancer, clinical trials Fri, 31 Mar 2017 00:00:00 +0100 Biosimilars Market, Europe, Forecast to 2025 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MCAA-01-00-00-00 Patent expiration and increased use of traditional generic drugs are leading to a shift of focus in the pharmaceutical industry toward investment in specialty drugs and high growth areas such as biosimilars. Expensive biopharmaceuticals are largely used for life-saving disorders such as cancer and diabetes, the incidence of which is increasing with population aging in Europe. Moreover, patent expiry of key product classes and a growing emphasis on cost effectiveness are making governments switch to affordable alternatives. There is thus a tremendous opportunity for biosimilar manufacturers. However, the development of biosimilar drugs is riddled with complexities, from R&D to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. About 30 companies are actively developing biosimilar medicines and are researching on the biosimilar versions of 16 distinct molecules that will lead to greater competition by 2020, with 8 major biologic medicines expected to lose exclusivity by 2020. The next five years are going to be an interesting period in the biosimilars market as a number of biologic drugs are going to lose their exclusivity. On the one hand, this will significantly reduce costs for patients and health systems, on the other, it will pose challenges for regulators to confirm the similarity of the biosimilar to the original biologic in terms of efficacy and safety. The experience of European healthcare companies has been encouraging in the 10 years since the endorsement of the first biosimilar in the EU. Pricing and physician awareness and support from the regulatory agencies are expected to be key factors driving success in the biosimilars market. Europe is expected to remain the largest contributor to biosimilars revenue worldwide for the next 5 7 years. The study analyzes the supply market dynamics and forecasts future revenues for key biosimilars in the European region. It also identifies the six key issues to determine the strategic imperatives for success and growth in this market. Moreover, it includes an in-depth analysis of the biosimilar value chain and the payer and regulatory environment. By assessing the impact of trends, disruptive technologies, and new business models, the study arrives at key visioning scenarios for the biosimilars market in Europe. These will help market participants make strategic decisions, stay ahead of their competitors, and gain a significant share in the market. The study also sheds light on strategic partnerships among companies in the European biosimilars market. Highlights of the report include: Growth Opportunities and Challenges Supply Market Dynamics Payer and Regulatory Environment Analysis Strategic Imperatives for Success and Growth The Six Tactical Issues Visioning Scenarios for the Biosimilars Market Business Model Essentials A Macro Overview of the Biosimilars Market Wed, 29 Mar 2017 00:00:00 +0100 3D Printing Systems in Healthcare, Forecast to 2020 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K124-01-00-00-00 Internal anatomy varies by shape and size based on factors such as gender, age, ethnicity, and body type. However, due to economies of scale, most implant manufacturers produce a range of standard sizes and assume that these implants will address the broadest range of patients needs. This few sizes fit all philosophy can result in mismatched sizes leading to complications such as post-operative pain, implant failure, and infection. With the advent of 3D printing, an implant can be tailor-made to the exact shape required by an individual ensuring a greater degree of fit and function. The key market drivers of 3D printing in healthcare include the growing demand for patient-specific products in orthopedics, dental, and maxillofacial surgery; enhanced productivity leading to reduced waiting periods for devices; and diminishing cost barriers associated with traditional product manufacturing. Wed, 29 Mar 2017 00:00:00 +0100 HIMSS17: The Race for Medical Imaging Analytics Ecosystems is Open. http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297443259 As we could glean from HIMSS17, seven major imaging and IT vendors are setting out to be the first to build and operationalize next-generation cloud-based platform for advanced imaging analytics. Fri, 24 Mar 2017 00:00:00 +0000 Innovations in Medical Imaging http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-12-00-00 The latest issue of Medical and Diagnostic Imaging TOE profiles innovations in medical imaging. Some of the profiles covered include optical biopsy technique for screening prostate cancer, low dose 3D dental imaging, angiography for intraoperative guidance, a non-invasive/non-ionizing imaging solution, elastography tool for assessment of liver health, and ultra-high frequency magnetic resonance imaging (MRI). Medical and Diagnostic Imaging TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Optical biopsy, 3D dental imaging, intraoperative guidance, non-ionizing imaging, elastography, liver health, ultra-high frequency MRI Fri, 24 Mar 2017 00:00:00 +0000 Recent Developments across Genetic Technologies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-3F-00-00 This Genetic Technology TOE depicts trends across genetic technologies. The corresponding clinical trial analysis for next-generation cancer immunotherapies is depicted, along with the industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: mitochondrial replacement therapy, cancer immunotherapies, Probody Therapeutics, AveXis, gene therapy candidate, AVXS-101, eGenesis, CRISPR technology, xenotransplantation Fri, 24 Mar 2017 00:00:00 +0000 Innovations in Big Data Analytics for Healthcare http://www.frost.com/prod/servlet/sublib/display-report.do?id=D78B-01-00-00-00 Big Data Analytics (BDA) refers to a set of data management tools, applications, and techniques for effective analysis of big datasets so as to derive intelligence on business operations and customer interactions. BDA is capable of processing both structured and unstructured data from various sources. This research provides a detailed understanding on how healthcare offers many opportunities where BDA could be applied to solve existing industry challenges, including coverage on identifying unmet needs, technology and application developments that enable innovations and drive market growth for care providers in the healthcare sector. The advent of BDA in health care offers the promise of dramatically transforming healthcare activities by providing better health monitoring, personalized healthcare and better maintenance of Electronic Health Records (EHR) . In brief, this research service provides the following: A brief overview of Big Data in healthcare sector. A snapshot on Drivers/Constraints. Brief overview on application of Big Data in health care innovations and research work. Technology convergence impacting health care. Disruptive opportunities and funding initiatives. Evaluating the technology road map and understanding key insights. Key patent and funding trends in Big Data. Thu, 23 Mar 2017 00:00:00 +0000 APAC Molecular Diagnostics Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P92E-01-00-00-00 The molecular diagnostics (MDx) market in APAC is witnessing rapid growth due to two main factors: the high adoption of MDx tests for infectious diseases applications in emerging countries, and the advent of innovative diagnostic solutions in cancer and NGS based solutions that are gaining pace in Asia. Multinational companies have not only identified Asia as a market for future growth but have significantly invested in R&D efforts to cater to the Asian population. Genomic studies on Asian population in disease areas like oncology for targeted therapies are constantly on a rise, with active efforts from pharmaceutical and IVD companies. The rise of the private healthcare sector in Asia, with the improvement of socio-economic conditions and the growth of a wealthy middle class, has increased the quest for affordable and quality healthcare across the region. The total MDx industry has been segmented into 4 major areas: infectious diseases, oncology, genetic disorders, and pharmacogenomics. The APAC MDx market was worth $1.72 Billion in 2016 and is expected to reach $2.86 Billion by 2021, at a CAGR of 10.7%. Infectious disease represents the highest market share of 72.0%, followed by oncology (14.3%), genetic disorders (10.0%) and pharmacogenomics (3.7%). Cancer incidence has gone up significantly in Asia. Under genetic disorders, non-invasive prenatal testing (NIPT) has great potential with excellent opportunities for future growth. On the technology front, conventional PCR technology is being upgraded with multiplexing capabilities and introduction of automated solutions to cater to high volumes. NGS solutions are gradually making inroads into Asia, especially in developed markets like Singapore, Japan, and South Korea. This study highlights the growing prominence of MDx industry in Asia, regional trends, growth opportunities, competitive dynamics, and a regional chapter for each of the 11 countries covered in this study. Area of opportunity in MDx market in the APAC: The MDx market in the APAC is evolving with increasing access to established NATs in emerging countries as a result of revamped healthcare practices across the region. Oncology care has taken a new dimension in APAC, with the simultaneous rise in prevalence and demand for innovative drugs beyond conventional chemotherapy drugs. CDx based oncology drugs are on the rise in the region, with studies targeted for Asian population to demonstrate value. For example, Ono Pharmaceutical s research on identifying a CDx for Opdivo, introduced in 2014 to stratify patient population. Novel genomic tools and technologies are foraying into the APAC to harness the future growth opportunities in the dynamic healthcare ecosystem. Key questions this study will answer: What is the impact of MDx on the IVD industry, given the present healthcare scenario in the APAC? Who are the key industry participants in this highly fragment market? What are multiple factors impending the growth of MDx in the APAC? What are the service delivery models adapted by stakeholders across this region? What are the market access strategies for MDx companies aspiring to enter the APAC? What is the future of the molecular diagnostics market in the APAC? Thu, 23 Mar 2017 00:00:00 +0000 Innovations in Biologic Therapeutics http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-3E-00-00 This Genetic Technology TOE depicts trends across biologic therapeutics. With every therapy that is being discovered, there are subsequent discoveries made on the ideal candidates for these therapies. Unfortunately, due to the genetic and cellular variability present in diseases such as cancer, certain therapies are more suitable for a specific strata of patients. The emergence of cell-based therapies and gene therapies will slowly revolutionize personalized therapeutics across diseases that are difficult to treat. The corresponding patent scenario is depicted, along with the industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Biologic therapeutics, chimeric antigen receptor T cell therapy, haematological malignancies, molecular switches, CAR-based T cell therapies, computational immunology, vaccine development, next generation biologic therapeutics, stem cells Fri, 17 Mar 2017 00:00:00 +0000 For Whom the Bill Tolls: The American Healthcare Act and its Implications http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297414305 The new healthcare bill unveiled by the Republicans has drawn sharp criticism from citizens, healthcare professionals, and policy makers on both sides of the aisle. Democrats see it as a large tax cut for the rich in the guise of a healthcare act while conservative Republicans feel that the new bill does not do enough to repeal Obamacare. Thu, 16 Mar 2017 00:00:00 +0000 Technologies for Cancer Research http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-0F-00-00 Cancer therapeutics are rapidly evolving with better targets and biologics. The greatest therapeutic current need is present across the indication of cancer. With each individual having a different and more unpredictable form of the disease, the need for personalized medicine is far greater. Hence, novel drug discovery technologies and drug delivery mechanisms are continuously being researched. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Cancer therapy, biologics, mAbs, antibodies, cancer treatment Fri, 10 Mar 2017 00:00:00 +0000 Advances in Prebiotic and Probiotic Therapies for Disorders of the Gastrointestinal Tract http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-3D-00-00 This Genetic Technology TOE depicts trends across prebiotic and probiotic therapies for disorders of the gastrointestinal tract. The corresponding analysis of leading prebiotic and probiotic companies, and the analysis of Top 20 companies with OTC prebiotics and probiotics are depicted along with industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Prebiotic therapies, probiotic therapies, gastrointestinal tract, lactose intolerance, inflammatory bowel disease, diarrhea management, yeasts, intestinal health Fri, 10 Mar 2017 00:00:00 +0000 Innovations in Prebiotic Sugar Substitutes http://www.frost.com/prod/servlet/sublib/display-report.do?id=D768-00-48-00-00 This Industrial Bioprocessing TOE features trends and innovations in healthcare sector. The TOE edition focusses on various technology innovations based on prebiotic sugar substitutes and provides insights on the funding scenario. Corresponding patents are also provided along with industry interactions. This Industrial Bioprocessing TOE features trends and innovations in biological solutions for treatment of plastic waste. Biological solutions are being explored by stakeholders to overcome the issues posed by thermochemical processes. The TOE focusses on various technology innovations in biological solutions for treatment of plastic waste and provides insights on technology adoption and funding scenario globally. Corresponding patents are also provided along with industry interactions. The Industrial Bioprocessing TechVision Opportunity Engine (TOE) provides intelligence on technologies, processes and strategic insights of industries involving bioprocessing, including innovations in the development and production of chemicals, pharmaceuticals, nutraceuticals, alternative fuels, chemical feedstocks, food and beverages, and consumer products. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Prebiotic sugar substitutes, insulin, inulin, oligosaccharide sugar substitutes, maltosyl-iso-malto-oligosaccharide, isomaltooligosaccharide, blood glucose management Fri, 10 Mar 2017 00:00:00 +0000 India s Excellent Standing in Biotechnology Drives Rapid Growth Opportunities http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297389298 The pharmaceuticals industry is one of the most rapidly growing sectors of the Indian biotechnology sector. Wed, 8 Mar 2017 00:00:00 +0000 3D Printing to Improve Quality of Life for Differentially Abled in Africa http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297381777 3D printing is a breakthrough technology that is set to revolutionize the global healthcare industry. One important application is the economic production of customised scaffolds or prosthetics (orthopaedic implants) to assist physically disabled people by substituting for lost or damaged bone. Mon, 6 Mar 2017 00:00:00 +0000 The Role of Data and Analytics in Improving Healthcare Management in South Africa http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297381980 Globally, the stakeholders of the healthcare industry are aware of two important priorities. First, the time taken for medical research to result in meaningful changes in clinical practice must reduce. Mon, 6 Mar 2017 00:00:00 +0000 Analysis of the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K0A6-01-00-00-00 Molecular imaging can easily be described as the next frontier of medical imaging. In an era of value-based reimbursement, molecular imaging is set to play a significant role in quicker diagnosis, more accurate disease staging, and selection of targeted treatments. Launch of new radiopharmaceuticals across clinical areas other than cardiology and oncology such as neurology and orthopedics is also expected to drive greater adoption of molecular imaging as part of clinical care pathways. However, molecular imaging continues to face several challenges, notably the high cost of molecular imaging modalities and image scans, competition from lower cost modalities such as CT and MRI, and concerns over future supply of Tc-99m, a key SPECT radiopharmaceutical used for cardiac scans. This study analyzes existing trends in the hybrid molecular imaging and diagnostic radiopharmaceuticals markets with an emphasis on understanding strategies employed by market participants to address these myriad challenges. It also assesses both these markets in the context of changing regulatory and reimbursement policies in order to provide future market trends. This analysis will be critical in helping market participants create long-term viable strategies in order to remain competitive and ensure continuous innovation. This deliverable assesses future trends in molecular imaging equipment revenues as well as growth in the number of unit shipments over the next few years. This will provide value to market participants that design and manufacture molecular imaging equipment. Market participants will also be provided insights on recent industry and technology trends that are shaping the molecular imaging market. Radiopharmaceutical manufacturers will be provided with key insights on the evolving usage trends of workhorse FDG and Tc-99m radiopharmaceuticals and the increasing adoption of new radiopharmaceuticals across new clinical areas. Companies that are in the process of developing software to improve quantitation accuracy, lower dosages, and reduce scan times for both PET and SPECT will be provided with key insights on how the molecular imaging market is growing as well as the factors that are required to facilitate greater adoption of PET and SPECT technologies. Mon, 6 Mar 2017 00:00:00 +0000 Technology Innovations in the Medical Device Industry http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-0F-00-00 The latest issue of the Medical Devices TOE profiles eight innovations spanning the breadth of the MedTech space. These include innovations in the biosensors space, which enable non-invasive and non-contact vital signs monitoring, advanced wound care technologies, minimally-invasive surgical technologies, and innovative cell therapies for bone healing. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Biosensors, ingestible sensors, vital signs monitoring, smart medical devices, bone healing Fri, 3 Mar 2017 00:00:00 +0000 Innovations in Disease Detection and Genetic Testing http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-3C-00-00 This Genetic Technology TOE depicts trends across disease detection and genetic testing. Genetic testing has been recommended by the American Society of Clinical Oncology (ASCO) for individuals with suspected cancer risk. The next generation gene sequencing panels help identify other family members at the risk of developing the disease. This study profiles key innovations in the field. The corresponding clinical trial assessment is depicted along with the industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Disease detection kit, genetic testing, next-generation gene sequencing, integrated genetic testing, personalized medicine, pan-cardio genes Fri, 3 Mar 2017 00:00:00 +0000 Biomarkers Enabling Diabetes and Obesity Management http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7A6-01-00-00-00 Obesity and diabetes are areas of growing concern across both, developed and developing countries. The rising geriatric population is likely to contribute to an increased prevalence of obesity and diabetes across the global landscape. Biomarker research is likely to facilitate the emergence of novel tools that may be useful for enhanced management of obesity, diabetes and related complications in the near future. There are several biomarkers that are currently being studied for predicting the risk and progression of several diseases such as type 2 diabetes, diabetic kidney disease, obesity and related disorders. Furthermore, companies are looking to leverage new biomarker-based platforms for early diagnosis and timely clinical management of obesity, diabetes and related complications. Biomarker-based research may also open novel paradigms for drug discovery and development obesity and diabetes disorders. Thu, 2 Mar 2017 00:00:00 +0000 5 Strategic Levers for Digital Health in Asia-Pacific http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297369748 Rising healthcare expenditure, ageing population, increasing incidence of chronic and infectious diseases and inefficient supply and management of hospital services are driving governments and providers in the Asia-Pacific (APAC) healthcare industry to explore alternative models of healthcare service delivery. Wed, 1 Mar 2017 00:00:00 +0000